Does Aetna (CVS Health) Cover Leqvio (Inclisiran)?

What Is Leqvio and Why Does Coverage Get Complicated?

Leqvio (inclisiran) is a small interfering RNA (siRNA) agent that silences PCSK9 synthesis in hepatocytes, reducing LDL-C by approximately 50% with twice-yearly dosing after the initial series. The FDA approved inclisiran in December 2021 for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional LDL-C lowering. 1

The twice-yearly administration schedule is clinically convenient but creates a billing complexity that most other lipid-lowering drugs avoid. Leqvio is administered in a physician's or clinic's office as a subcutaneous injection, which means it typically routes through the medical benefit rather than the pharmacy benefit on many Aetna plans. That distinction matters: medical-benefit drugs face different utilization-management rules and cost-sharing structures than pharmacy-benefit drugs, and prior authorization documentation must travel through a separate channel. 2

Patients and prescribers should confirm which benefit bucket applies before submitting any PA paperwork, because a pharmacy PA submitted for a medical-benefit drug will be rejected on procedural grounds, not clinical grounds.

Aetna (CVS Health) Formulary Status for Leqvio

Leqvio sits on a specialty tier (typically Tier 4 or Tier 5) across Aetna commercial PPO and HMO formularies. Specialty-tier placement reflects the drug's price point and the insurer's desire to gate access through clinical review. 3

On the pharmacy side, CVS Caremark (Aetna's pharmacy benefit manager) lists inclisiran as a covered specialty drug with prior authorization required. On the medical side, Aetna's clinical policy bulletins govern coverage under J-code billing. The relevant CPB typically groups inclisiran with other PCSK9-directed therapies, including evolocumab (Repatha) and alirocumab (Praluent), and applies a shared set of step-therapy and LDL-C threshold criteria across all three agents. 4

Formulary coverage can vary by specific plan design (individual market, small group, large group, Medicare Advantage). Medicare Part B patients face a distinct coverage analysis under CMS rules rather than Aetna's commercial clinical policy. Always pull the current Summary of Benefits and Coverage (SBC) for the exact plan year.

Prior Authorization Criteria: What Aetna Requires

Aetna's prior authorization criteria for Leqvio generally require all of the following. First, a confirmed diagnosis of HeFH or clinical ASCVD, documented by ICD-10 code and clinical notes. The ACC/AHA 2019 Guideline on the Management of Blood Cholesterol defines very-high-risk ASCVD as two or more major ASCVD events or one major event plus multiple high-risk conditions. 5 Second, an LDL-C of 70 mg/dL or above (for ASCVD) or 100 mg/dL or above (for HeFH without ASCVD) on maximally tolerated therapy. Third, documentation that the patient has tried and failed, or is intolerant of, at least one high-intensity statin, most commonly atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg. Fourth, documented concurrent use of ezetimibe 10 mg, or documented intolerance with specific contraindication. Fifth, the prescriber must be a cardiologist, lipidologist, or internist actively managing cardiovascular risk. 6

The clinical evidence supporting these thresholds is substantial. In ORION-10 (N=1,561, high-intensity statin background), inclisiran 284 mg reduced LDL-C by a placebo-adjusted 52.3% at day 510 (P<0.001). 7 ORION-11 (N=1,617, mixed statin background) showed a placebo-adjusted LDL-C reduction of 49.9% at day 510 (P<0.001). 8 Both trials fed into the FDA's approval and are the primary data Aetna's medical directors review when adjudicating claims.

Step Therapy Requirements

Aetna requires step therapy before Leqvio for the vast majority of commercially insured patients. The expected sequence is: (1) high-intensity statin titrated to maximally tolerated dose, (2) addition of ezetimibe 10 mg, (3) documentation that LDL-C remains above threshold despite steps one and two, and only then (4) PCSK9-directed therapy. 9

Some plans additionally require a trial of bempedoic acid (Nexletol) or the combination tablet bempedoic acid/ezetimibe (Nexlizet) before approving a PCSK9 agent. This is not universal across all Aetna plan designs but appears in select large-group and self-insured plans administered by Aetna. Prescribers should check the specific step-edit protocol using Aetna's NaviMedical or NaviCare PA portal before initiating the request.

Step therapy exemptions exist. Patients with complete statin intolerance documented by creatine kinase (CK) elevation, myopathy diagnosis, or rhabdomyolysis history may bypass the statin step. Similarly, patients with a recent acute coronary syndrome (ACS) within 90 days may qualify for expedited review, consistent with ACC/AHA guideline language recommending high-intensity or maximally tolerated lipid-lowering therapy promptly after ACS. 10

How to Submit a Prior Authorization for Leqvio

The prescriber or clinical staff must gather specific documents before opening the PA case. Required items typically include: a clinical note confirming diagnosis and cardiovascular risk category, current fasting lipid panel (dated within 90 days), evidence of current statin prescription with dose, evidence of current ezetimibe prescription or documented intolerance, and a pharmacy or medical claim history showing at least 60 to 90 days on optimized oral therapy. 11

Submission channels for Aetna commercial plans include the Availity provider portal, direct fax to Aetna's pharmacy management unit, and phone-based PA through Aetna Provider Services. The standard review turnaround is 72 hours for non-urgent requests; urgent requests involving acute cardiovascular risk must be processed within 24 hours under most state prompt-pay and utilization-management laws. 12

A complete, well-documented PA submission cuts denial rates significantly. Submissions that omit the LDL-C value or the step-therapy medication history are the most common reasons for initial technical denial rather than a clinical denial, which is a fixable problem.

What Happens After an Aetna Denial

A denial letter from Aetna must state the specific clinical reason under ERISA and state insurance regulations. Read that reason carefully: a denial for "step therapy not met" requires different supporting documentation than a denial for "indication not covered" or "not medically necessary." 13

The appeal pathway has three levels. A first-level internal appeal must be filed within 180 days of the denial date on most commercial plans. The appeal packet should include a letter of medical necessity from the prescribing cardiologist or lipidologist, any relevant peer-reviewed publications (ORION-10, ORION-11 are appropriate), the patient's full lipid history spanning at least 12 months, documentation of all prior lipid-lowering therapies with dates and doses, and any documented adverse effects from statins. 14

If the first-level internal appeal is denied, a second-level internal appeal or an external independent review is available. External reviews are conducted by accredited independent review organizations (IROs) that apply clinical criteria independently of Aetna's policies. External reviews of PCSK9 agents have a meaningful overturn rate, particularly when the prescribing clinician submits a detailed, guideline-referenced medical necessity letter. 15

The HealthRX denial-to-approval framework for Leqvio follows four checkpoints. Checkpoint one: confirm the denial reason in writing. Checkpoint two: collect 12 months of lipid-panel trend data showing LDL-C persistently above threshold. Checkpoint three: have the treating cardiologist or lipidologist write a letter citing the specific ACC/AHA guideline class of recommendation (Class IIa, LOE A for PCSK9 inhibitors in very-high-risk ASCVD with LDL-C 70 mg/dL or above on maximally tolerated therapy). Checkpoint four: file the appeal with all attachments by certified mail or electronic portal confirmation to create a timestamped record. This four-checkpoint approach addresses the most common grounds for external review overturn.

Aetna Medicare Advantage Plans and Leqvio

Medicare Advantage plan coverage of Leqvio differs from commercial coverage. CMS does not mandate that MA plans cover inclisiran on Part D formularies, and many MA plans have not yet placed inclisiran on their Part D drug lists because of its medical-benefit routing. Patients enrolled in an Aetna Medicare Advantage plan should specifically ask whether inclisiran is covered under Part B (medical benefit, J-code J3490 or a dedicated J-code if assigned) rather than Part D. 16

Part B drugs under Medicare Advantage are generally covered at 80% after the Part B deductible, with supplemental (Medigap) coverage potentially covering the remaining 20%. The 2023 IRA drug-price negotiation provisions affect a separate drug list and do not currently include inclisiran, though CMS continues to expand the list annually. 17

Cost Without Coverage and Manufacturer Assistance

The manufacturer list price for inclisiran runs approximately $3,250 per single-dose injection. The year-one regimen involves three injections (day 1, month 3, month 6), translating to roughly $9,750 at list price. Maintenance dosing is two injections per year, approximately $6,500 annually at list. These figures represent WAC (wholesale acquisition cost) and do not reflect rebates negotiated by PBMs. 18

Novartis offers the Leqvio Together patient support program, which provides co-pay assistance for commercially insured patients and a separate free-drug program for uninsured or underinsured patients who meet income criteria. Commercially insured patients using the co-pay card may pay as little as $0 per dose, subject to annual benefit maximums and state restrictions (the card is not valid for Medicare or Medicaid beneficiaries). 19

Patients should enroll in Leqvio Together before the first injection appointment so the co-pay card is active. The program can be reached through Novartis's direct patient support line, and enrollment does not require physician involvement beyond the prescription itself.

Does Aetna Cover Leqvio for Conditions Beyond ASCVD and HeFH?

The FDA label covers HeFH and clinical ASCVD in adults. Aetna's coverage policy follows the label; off-label use for other dyslipidemias, including homozygous familial hypercholesterolemia (HoFH), would not be approved without compelling peer-reviewed literature and a specialty consultation note. HoFH is typically treated with lomitapide (Juxtapid) or evinacumab (Evkeeza), which have separate formulary pathways. 20

There is no FDA-approved indication for inclisiran as a weight-loss agent, and Aetna will not approve it for that purpose. Any submission citing obesity or metabolic syndrome as the primary diagnosis will be denied. The indication must be cardiovascular in nature, specifically LDL-C reduction in HeFH or ASCVD.

Clinical Evidence That Supports Your Appeal

Prescribers preparing appeal documentation should reference the following trial data directly. ORION-10 enrolled 1,561 patients with ASCVD on background statin therapy. Inclisiran 284 mg produced a time-averaged LDL-C reduction of 51.3% versus placebo at day 510 (P<0.001). 21 ORION-11 enrolled 1,617 patients with ASCVD or ASCVD risk equivalents. Inclisiran produced a time-averaged LDL-C reduction of 49.9% versus placebo (P<0.001). 22 A pooled analysis of the ORION program published in JAMA Cardiology confirmed the consistency of these results across subgroups including diabetic patients, elderly patients, and those with chronic kidney disease. 23

The 2022 ACC Expert Consensus Decision Pathway on novel therapies for LDL-C lowering assigns inclisiran a Class IIa recommendation for patients with clinical ASCVD or HeFH who remain above LDL-C threshold on maximally tolerated statin plus ezetimibe. The ACC pathway states: "For patients who require additional LDL-C lowering, PCSK9 inhibitors or inclisiran are reasonable options given their demonstrated efficacy and safety profiles." 24 Citing this consensus document by name and class of recommendation in an appeal letter materially strengthens the medical necessity argument.

What Aetna Means by "Maximally Tolerated Statin"

Aetna's PA criteria use the phrase "maximally tolerated statin," and medical reviewers apply this phrase strictly. It does not mean the patient tried one statin at one dose. It means the patient trialed at least one high-intensity statin (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) and, if intolerant, documented that intolerance with a reason (muscle symptoms with CK elevation, hepatotoxicity, rhabdomyolysis). 25

A trial of pravastatin 10 mg that was stopped for a minor complaint does not qualify as maximally tolerated therapy in most Aetna reviewer interpretations. Prescribers should be specific: "Patient trialed atorvastatin 80 mg for 90 days and developed confirmed statin-associated muscle symptoms with CK 4x ULN; subsequently trialed rosuvastatin 10 mg (reduced-dose attempt) for 60 days with recurrent myalgia. Currently maintained on rosuvastatin 5 mg twice weekly as maximally tolerated dose per ACC statin intolerance guidance." That level of detail passes medical review at a higher rate.

Statin Intolerance Documentation Strategy

If the patient's primary barrier to LDL-C goal is statin intolerance rather than simply inadequate response, the prescriber's documentation must meet a higher evidentiary bar. Aetna's reviewers are trained to distinguish between patients who refuse statins and patients who have documented adverse effects. 26

Objective evidence of statin intolerance includes: CK levels drawn during a symptomatic period (not baseline), ALT/AST elevation to 3x ULN or above, or a documented rechallenge attempt that reproduced symptoms. A patient who develops myalgia on atorvastatin, tolerates rosuvastatin 5 mg without CK elevation but still has LDL-C above 70 mg/dL, is a strong candidate for PCSK9-directed therapy. The clinical note should state the current LDL-C, the current statin dose, and the specific reason the statin cannot be further uptitrated. 27

Timing and Resubmission After Denial

A denied PA should generally be resubmitted within 30 days with additional documentation rather than waiting for the standard appeal clock to run. Resubmission with supplemental records is treated as a new clinical review under Aetna's processing rules and does not consume the 180-day appeal window. 28

If the PA is denied on the same clinical grounds after resubmission, the formal internal appeal process begins. Keep copies of every submission, every fax confirmation, and every portal acknowledgment. These records establish the timeline if the case escalates to an external IRO review or, in the case of fully insured plans, a state insurance commissioner complaint.

Working With Aetna's Specialty Pharmacy Network

When Leqvio routes through the pharmacy benefit rather than the medical benefit on certain plan designs, Aetna requires dispensing through a CVS Specialty or in-network specialty pharmacy. This is not optional: dispensing through a retail pharmacy or an out-of-network specialty pharmacy will result in a claim rejection regardless of whether the PA was approved. 29

The clinical staff should confirm the dispensing channel at the time of PA submission, not at the time of injection. For office-administered doses (the more common pathway), the drug is typically ordered under buy-and-bill or through a limited distribution channel designated by Novartis, with the administering provider billing Aetna directly under the medical benefit using the appropriate J-code.